RadNet, Inc. vs VERACYTE, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
What is priced in: Veracyte at 56 times earnings is priced for genomic-test menus to keep compounding at software margins; RadNet, with no earnings to price at all, is priced for imaging volume to eventually outrun wage and rate pressure. The economics are night and day, a 16.3% operating margin against negative 4.2%, a 72.7% gross margin against undisclosed-but-thin. RadNet's consolation is cash, a 7.2% free-cash yield from depreciation accounting against Veracyte's 3.2%; its burden is 0.82 turns of debt against none. Equal market values, $5B each. The market has priced the chemistry and the real estate of diagnostics identically; the income statements object, loudly.
Comparison updated 2026-07-10.
| Metric | RDNT | VCYT |
|---|---|---|
| Price | $60.71 | $60.46 |
| Market cap | $4.7B | $4.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | — | 56.0 |
| P/B | 3.46 | 3.66 |
| P/S | 2.18 | 9.07 |
| EV/EBITDA | 23.8 | 56.1 |
| Revenue growth | +14.7% | +16.9% |
| Gross margin | — | 72.7% |
| Operating margin | -4.2% | 16.3% |
| Net margin | -0.7% | 16.3% |
| Return on equity | -1.1% | 6.5% |
| Return on assets | -0.4% | 6.1% |
| Return on invested capital | 2.0% | 5.5% |
| FCF yield | 7.2% | 3.2% |
| Debt / equity | 0.82 | 0.00 |
| Current ratio | 1.17 | 9.31 |
| Altman Z (solvency) | 1.63 | 6.48 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.